Human TRAIL/TNFSF10 ELISA Kit - Quantikine

Catalog # Availability Size / Price Qty
DTRL00
Control Products Available
Human TRAIL/TNFSF10 ELISA Cell Culture Supernate/Cell Lysate/Saliva Standard Curve
3 Images
Product Details
Procedure
Citations (36)
FAQs
Supplemental Products
Reviews (1)

Human TRAIL/TNFSF10 Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (50 uL), Cell Lysates (50 uL), Serum (50 uL), EDTA Plasma (50 uL), Heparin Plasma (50 uL), Saliva (25 uL)
Sensitivity
7.87 pg/mL
Assay Range
15.6 - 1,000 pg/mL (Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma, Saliva)
Specificity
Natural and recombinant human TRAIL
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.Cross-species reactivity not tested.
Interference
Interference observed with 1 or more available related molecules.

Product Summary

The Quantikine Human TRAIL Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human TRAIL in cell culture supernates, serum, plasma, cell lysates, and saliva. It contains NS0-expressed recombinant human TRAIL and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human TRAIL showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for natural human TRAIL

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision

Cell Culture Supernates, Cell Lysates, Saliva

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/mL) 95 193 391 96 191 388
Standard Deviation 4.26 8.81 24.3 8.3 14.8 22.2
CV% 4.5 4.6 6.2 8.6 7.7 5.7

Serum, EDTA Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean (pg/mL) 102 203 408 102 202 407
Standard Deviation 3.45 5.73 23 7.59 12.2 17.8
CV% 3.4 2.8 5.6 7.5 6.1 4.4

Recovery

The recovery of TRAIL spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 101 92-105
EDTA Plasma (n=4) 103 96-112
Heparin Plasma (n=4) 103 98-115
Serum (n=4) 96 91-102

Linearity

To assess the linearity of the assay, samples containing or spiked with high concentrations of TRAIL were serially diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human TRAIL/TNFSF10 ELISA Linearity

Scientific Data

Human TRAIL/TNFSF10 ELISA Cell Culture Supernate/Cell Lysate/Saliva Standard Curve

Human TRAIL/TNFSF10 ELISA Serum/Plasma Standard Curve

Product Datasheets

You must select a language.

x

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: TRAIL/TNFSF10

TNF-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand and TNFSF10, is a type II transmembrane protein with a carboxy-terminal extracellular domain that exhibits homology to other TNF superfamily members. Among TNF superfamily members, TRAIL is the most homologous to Fas Ligand, sharing 28% amino acid sequence identity in their extracellular domains. Human TRAIL shares 65% amino acid sequence identity with mouse TRAIL and is active on mouse cells.

Long Name:
TNF-related Apoptosis-inducing Ligand
Entrez Gene IDs:
8743 (Human); 22035 (Mouse); 246775 (Rat)
Alternate Names:
Apo-2 ligand; APO2L; Apo-2Ltumor necrosis factor (ligand) family, member 10; APO2Ltumor necrosis factor apoptosis-inducing ligand splice variant delta; CD253 antigen; CD253; Protein TRAIL; TL2; TNF-related apoptosis-inducing ligand; TNFSF10; TRAIL; TRAILTNF-related apoptosis inducing ligand TRAIL; tumor necrosis factor (ligand) superfamily, member 10; tumor necrosis factor ligand superfamily member 10
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 50 µL Standard, Control, or Sample
  6.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours on a horizontal orbital microplate shaker.
  7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours on the shaker.
  10.   Aspirate and wash 4 times.

  11. 200 µL Substrate Solution
  12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes on the benchtop. PROTECT FROM LIGHT.

  13. 50 µL Stop Solution
  14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human TRAIL/TNFSF10 Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

36 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. CRISPR screens identify novel regulators of cFLIP dependency and ligand-independent, TRAIL-R1-mediated cell death
    Authors: N Kuehnle, SM Osborne, Z Liang, M Manzano, E Gottwein
    Cell Death and Differentiation, 2023-02-18;0(0):.
    Species: Human
    Sample Types: Cell Culture Supernates
  2. Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures
    Authors: S Ravichandr, G Grubbs, J Tang, Y Lee, C Huang, H Golding, S Khurana
    Science Advances, 2021-10-13;7(42):eabi6533.
    Species: Human
    Sample Types: Nasal Lavage Fluid
  3. Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Proximal Tubular Epithelial Cells through miR-545-3p-TNFSF10
    Authors: MC Kuo, WA Chang, LY Wu, YC Tsai, YL Hsu
    Biomolecules, 2021-07-15;11(7):.
    Species: Human
    Sample Types: Cell Culture Supernates
  4. Engineering of Doxorubicin-Encapsulating and TRAIL-Conjugated Poly(RGD) Proteinoid Nanocapsules for Drug Delivery Applications
    Authors: E Hadad, S Rudnick-Gl, E Itzhaki, MY Avivi, I Grinberg, Y Elias, S Margel
    Polymers, 2020-12-16;12(12):.
    Species: Human
    Sample Types: Cell Culture Supernates
  5. Identification of pathogenic TRAIL-expressing innate immune cells during HIV-1 infection in humanized mice by scRNA-Seq
    Authors: L Cheng, H Yu, JA Wrobel, G Li, P Liu, Z Hu, XN Xu, L Su
    JCI Insight, 2020-06-04;5(11):.
    Species: Humanized Mouse
    Sample Types: Plasma
  6. M1 Macrophages Promote TRAIL Expression in Adipose Tissue-Derived Stem Cells, Which Suppresses Colitis-Associated Colon Cancer by Increasing Apoptosis of CD133+ Cancer Stem Cells and Decreasing M2 Macrophage Population
    Authors: YW Eom, R Akter, W Li, S Lee, S Hwang, J Kim, MY Cho
    Int J Mol Sci, 2020-05-29;21(11):.
    Species: Human
    Sample Types: Cell Culture Supernates
  7. Efficient recruitment of c-FLIPL to the death-inducing signaling complex leads to Fas resistance in natural killer-cell lymphoma
    Authors: A Masuda, Y Isobe, K Sugimoto, M Yoshimori, A Arai, N Komatsu
    Cancer Sci., 2020-01-31;111(3):807-816.
    Species: Human
    Sample Types: Cell Culture Supernates
  8. Circulating cell death biomarker TRAIL is associated with increased organ dysfunction in sepsis
    Authors: EJ Schenck, KC Ma, DR Price, T Nicholson, C Oromendia, ER Gentzler, E Sanchez, RM Baron, LE Fredenburg, JW Huh, II Siempos, AM Choi
    JCI Insight, 2019-05-02;4(9):.
    Species: Human
    Sample Types: Plasma
  9. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer
    Authors: C Spano, G Grisendi, G Golinelli, F Rossignoli, M Prapa, M Bestagno, O Candini, T Petrachi, A Recchia, F Miselli, G Rovesti, G Orsi, A Maiorana, P Manni, E Veronesi, MS Piccinno, A Murgia, M Pinelli, EM Horwitz, S Cascinu, P Conte, M Dominici
    Sci Rep, 2019-02-11;9(1):1788.
    Species: Human
    Sample Types: Cell Culture Supernates
  10. MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma
    Authors: F Rossignoli, C Spano, G Grisendi, EM Foppiani, G Golinelli, I Mastrolia, M Bestagno, O Candini, T Petrachi, A Recchia, F Miselli, G Rovesti, G Orsi, E Veronesi, G Medici, B Petocchi, M Pinelli, EM Horwitz, P Conte, M Dominici
    Theranostics, 2019-01-01;9(2):436-448.
    Species: Human
    Sample Types: Cell Culture Supernates
  11. Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease
    Authors: MV Arcidiacon, E Rimondi, E Maietti, E Melloni, V Tisato, S Gallo, JM Valdiviels, E Fernández, À Betriu, R Voltan, G Zauli, S Volpato, P Secchiero
    PLoS ONE, 2018-09-11;13(9):e0203716.
    Species: Human
    Sample Types: Serum
  12. TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress
    Authors: V Tisato, S Gallo, E Melloni, C Celeghini, A Passaro, G Zauli, P Secchiero, C Bergamini, A Trentini, G Bonaccorsi, G Valacchi, G Zuliani, C Cervellati
    Mediators Inflamm., 2018-07-26;2018(0):9629537.
    Species: Human
    Sample Types: Serum
  13. TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia
    Authors: J Yang, FR LeBlanc, SA Dighe, CE Hamele, TL Olson, DJ Feith, TP Loughran
    Blood, 2018-04-26;0(0):.
    Species: Human
    Sample Types: Serum
  14. Lower maternal serum tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in early preeclampsia. A retrospective study
    Authors: D Morano, A Rolfo, V Tisato, A Farina, E Rimondi, G Scutiero, P Greco, G Bonaccorsi, T Todros
    Pregnancy Hypertens, 2018-02-07;12(0):1-5.
    Species: Human
    Sample Types: Serum
  15. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
    Authors: J Wagner, CL Kline, L Zhou, V Khazak, WS El-Deiry
    J. Exp. Clin. Cancer Res., 2018-01-22;37(1):11.
    Species: Mouse
    Sample Types: Serum
  16. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.
    Authors: Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J, Walker W, McNally K, Lim W
    Cell, 2016-09-29;167(2):419-432.e16.
    Species: Human
    Sample Types: Cell Culture Supernates
  17. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
    Sci Rep, 2016-07-12;6(0):29713.
    Species: Human
    Sample Types: Serum
  18. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
    Nat Commun, 2016-05-20;7(0):11589.
    Species: Human
    Sample Types: Plasma
  19. TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.
    Authors: Mohr A, Yu R, Zwacka R
    BMC Cancer, 2015-07-03;15(0):494.
    Species: Human
    Sample Types: Cell Culture Supernates
  20. TRAIL Is Decreased Before 20 Weeks Gestation in Women with Hypertensive Disorders of Pregnancy.
    Authors: Zhou C, Long Y, Yang H, Zhu C, Ma Q, Zhang Y
    PLoS ONE, 2015-06-01;10(6):e0128425.
    Species: Human
    Sample Types: Plasma
  21. Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas.
    Authors: Choi S, Lee Y, Kwak P, Lee J, Kim S, Lee S, Phi J, Wang K, Song J, Song S, Joo K, Kim S
    Cancer Gene Ther, 2015-05-29;22(6):302-11.
    Species: Human
    Sample Types: Cell Culture Supernates
  22. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest.
    Authors: Kang S, Kang D, Bakhtiar Ul Islam S, Je S, Kim J, Song J
    Cell Signal, 2015-03-05;27(6):1214-24.
    Species: Human
    Sample Types: Cell Culture Supernates
  23. Systemic anticancer neural stem cells in combination with a cardiac glycoside for glioblastoma therapy.
    Authors: Teng J, Hejazi S, Badr C, Tannous B
    Stem Cells, 2014-08-01;32(8):2021-32.
    Species: Human, Mouse
    Sample Types: Cell Culture Supernates, Whole Tissue
  24. A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.
    Authors: Ray A, Tian Z, Das D, Coffman R, Richardson P, Chauhan D, Anderson K
    Leukemia, 2014-01-30;28(8):1716-24.
    Species: Human
    Sample Types: Cell Culture Supernates
  25. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function.
    Authors: Zhang Y, Patel B, Dey A, Ghorani E, Rai L, Elham M, Castleton AZ, Fielding AK
    J. Immunol., 2011-12-16;188(3):1002-10.
    Species: Human
    Sample Types: Cell Culture Supernates
  26. Potential role of soluble TRAIL in epithelial injury in children with severe RSV infection.
    Authors: Bem RA, Bos AP, Wosten-van Asperen RM, Bruijn M, Lutter R, Sprick MR, van Woensel JB
    Am. J. Respir. Cell Mol. Biol., 2009-07-27;42(6):697-705.
    Species: Human
    Sample Types: BALF
  27. Prognostic value of apoptosis markers in advanced heart failure patients.
    Authors: Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B, Hulsmann M, Berger R, Mortl D, Huber K, Wojta J, Pacher R
    Eur. Heart J., 2009-02-04;30(7):789-96.
    Species: Human
    Sample Types: Plasma
  28. Conjunctival sac fluid contains elevated levels of soluble TRAIL: implications for the anti-tumoral surveillance of the anterior surface of the eye.
    Authors: Secchiero P, Lamberti G, Corallini F, Melloni E, Guarnotta C, Sebastiani A, Zauli G
    J. Cell. Physiol., 2009-01-01;218(1):199-204.
    Species: Human
    Sample Types: Conjunctival Fluid
  29. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
    Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
    Stem Cells, 2008-09-04;26(11):2955-63.
    Species: Human
    Sample Types: Cell Culture Supernates
  30. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway.
    Authors: Chamoux E, Houde N, L'Eriger K, Roux S
    J. Cell. Physiol., 2008-08-01;216(2):536-42.
    Species: Human
    Sample Types: Cell Culture Supernates
  31. TRAIL limits excessive host immune responses in bacterial meningitis.
    Authors: Hoffmann O, Priller J, Prozorovski T, Schulze-Topphoff U, Baeva N, Lunemann JD, Aktas O, Mahrhofer C, Stricker S, Zipp F, Weber JR
    J. Clin. Invest., 2007-07-01;117(7):2004-13.
    Species: Human
    Sample Types: CSF
  32. Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro.
    Authors: Corallini F, Celeghini C, Rizzardi C, Pandolfi A, Di Silvestre S, Vaccarezza M, Zauli G
    J. Cell. Physiol., 2007-07-01;212(1):89-95.
    Species: Human
    Sample Types: Serum
  33. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
    Authors: Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, Faber P, Bukowski R, Tong K, Borden EC
    Clin. Pharmacol. Ther., 2007-03-01;81(3):354-61.
    Species: Human
    Sample Types: Serum
  34. Erythropoiesis abnormalities contribute to early-onset anemia in patients with septic shock.
    Authors: Claessens YE, Fontenay M, Pene F, Chiche JD, Guesnu M, Hababou C, Casadevall N, Dhainaut JF, Mira JP, Cariou A
    Am. J. Respir. Crit. Care Med., 2006-03-30;174(1):51-7.
    Species: Human
    Sample Types: Plasma
  35. HIV-1 tat protein and cell proliferation and survival: a brief review.
    Authors: Gibellini D, Vitone F, Schiavone P, Re MC
    New Microbiol., 2005-04-01;28(2):95-109.
    Species: Human
    Sample Types: Plasma
  36. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes.
    Authors: Campioni D, Secchiero P, Corallini F, Melloni E, Capitani S, Lanza F, Zauli G
    Am. J. Pathol., 2005-02-01;166(2):557-63.
    Species: Human
    Sample Types: Cell Culture Supernates

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
Loading...

Reviews for Human TRAIL/TNFSF10 Quantikine ELISA Kit

Average Rating: 5 (Based on 1 Review)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human TRAIL/TNFSF10 Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human TRAIL/TNFSF10 Quantikine ELISA Kit
By Adam Guess on 10/04/2017
Sample Tested: Cell Culture Supernates